Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Promising Colorectal Cancer Biomarkers for Precision Prevention and Therapy.

Turano M, Delrio P, Rega D, Cammarota F, Polverino A, Duraturo F, Izzo P, De Rosa M.

Cancers (Basel). 2019 Dec 4;11(12). pii: E1932. doi: 10.3390/cancers11121932. Review.

2.

Mindfulness Meditation Is Related to Long-Lasting Changes in Hippocampal Functional Topology during Resting State: A Magnetoencephalography Study.

Lardone A, Liparoti M, Sorrentino P, Rucco R, Jacini F, Polverino A, Minino R, Pesoli M, Baselice F, Sorriso A, Ferraioli G, Sorrentino G, Mandolesi L.

Neural Plast. 2018 Dec 18;2018:5340717. doi: 10.1155/2018/5340717. eCollection 2018.

3.

Treating TB human neuroectodermal cell line with retinoic acid induces the appearance of neuron-like voltage-gated ionic currents.

Santillo S, Martini A, Polverino A, Mercuri NB, Guatteo E, Sorrentino G.

Brain Res. 2019 May 15;1711:97-105. doi: 10.1016/j.brainres.2019.01.019. Epub 2019 Jan 17.

PMID:
30660613
4.

Effects of Physical Exercise on Cognitive Functioning and Wellbeing: Biological and Psychological Benefits.

Mandolesi L, Polverino A, Montuori S, Foti F, Ferraioli G, Sorrentino P, Sorrentino G.

Front Psychol. 2018 Apr 27;9:509. doi: 10.3389/fpsyg.2018.00509. eCollection 2018. Review.

5.

Effects of Acetylcholine on β-Amyloid-Induced cPLA2 Activation in the TB Neuroectodermal Cell Line: Implications for the Pathogenesis of Alzheimer's Disease.

Polverino A, Grimaldi M, Sorrentino P, Jacini F, D'Ursi AM, Sorrentino G.

Cell Mol Neurobiol. 2018 May;38(4):817-826. doi: 10.1007/s10571-017-0555-4. Epub 2017 Oct 9.

PMID:
28993924
6.

Environmental Factors Promoting Neural Plasticity: Insights from Animal and Human Studies.

Mandolesi L, Gelfo F, Serra L, Montuori S, Polverino A, Curcio G, Sorrentino G.

Neural Plast. 2017;2017:7219461. doi: 10.1155/2017/7219461. Epub 2017 Jun 14. Review.

7.

The dark sides of amyloid in Alzheimer's disease pathogenesis.

Sorrentino P, Iuliano A, Polverino A, Jacini F, Sorrentino G.

FEBS Lett. 2014 Mar 3;588(5):641-52. doi: 10.1016/j.febslet.2013.12.038. Epub 2014 Jan 31. Review. Erratum in: FEBS Lett. 2014 Dec 20;588(24):4838.

8.

Cortical metabolic deficits in a rat model of cholinergic basal forebrain degeneration.

Gelfo F, Petrosini L, Graziano A, De Bartolo P, Burello L, Vitale E, Polverino A, Iuliano A, Sorrentino G, Mandolesi L.

Neurochem Res. 2013 Oct;38(10):2114-23. doi: 10.1007/s11064-013-1120-2. Epub 2013 Aug 8.

PMID:
23925861
9.

Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models.

Coxon A, Ziegler B, Kaufman S, Xu M, Wang H, Weishuhn D, Schmidt J, Sweet H, Starnes C, Saffran D, Polverino A.

Mol Cancer. 2012 Sep 19;11:70. doi: 10.1186/1476-4598-11-70.

10.

Anti-tumor activity of motesanib in a medullary thyroid cancer model.

Coxon A, Bready J, Kaufman S, Estrada J, Osgood T, Canon J, Wang L, Radinsky R, Kendall R, Hughes P, Polverino A.

J Endocrinol Invest. 2012 Feb;35(2):181-90. doi: 10.3275/7609. Epub 2011 Mar 21.

PMID:
21422803
11.

Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors.

Caenepeel S, Renshaw-Gegg L, Baher A, Bush TL, Baron W, Juan T, Manoukian R, Tasker AS, Polverino A, Hughes PE.

J Exp Clin Cancer Res. 2010 Jul 15;29:96. doi: 10.1186/1756-9966-29-96.

12.

Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors.

Kruser TJ, Wheeler DL, Armstrong EA, Iida M, Kozak KR, van der Kogel AJ, Bussink J, Coxon A, Polverino A, Harari PM.

Clin Cancer Res. 2010 Jul 15;16(14):3639-47. doi: 10.1158/1078-0432.CCR-09-3385. Epub 2010 May 27.

13.

Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.

Coxon A, Bush T, Saffran D, Kaufman S, Belmontes B, Rex K, Hughes P, Caenepeel S, Rottman JB, Tasker A, Patel V, Kendall R, Radinsky R, Polverino A.

Clin Cancer Res. 2009 Jan 1;15(1):110-8. doi: 10.1158/1078-0432.CCR-08-1155.

14.

Evaluation of indazole-based compounds as a new class of potent KDR/VEGFR-2 inhibitors.

Bauer D, Whittington DA, Coxon A, Bready J, Harriman SP, Patel VF, Polverino A, Harmange JC.

Bioorg Med Chem Lett. 2008 Sep 1;18(17):4844-8. doi: 10.1016/j.bmcl.2008.07.080. Epub 2008 Jul 24.

PMID:
18682324
15.

Discovery of novel 1,2,3,4-tetrahydroisoquinolines and 3,4-dihydroisoquinoline-1(2H)-ones as potent and selective inhibitors of KDR: synthesis, SAR, and pharmacokinetic properties.

Choquette D, Teffera Y, Polverino A, Harmange JC.

Bioorg Med Chem Lett. 2008 Jul 15;18(14):4054-8. doi: 10.1016/j.bmcl.2008.05.114. Epub 2008 Jun 4.

PMID:
18573658
16.

Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.

Harmange JC, Weiss MM, Germain J, Polverino AJ, Borg G, Bready J, Chen D, Choquette D, Coxon A, DeMelfi T, DiPietro L, Doerr N, Estrada J, Flynn J, Graceffa RF, Harriman SP, Kaufman S, La DS, Long A, Martin MW, Neervannan S, Patel VF, Potashman M, Regal K, Roveto PM, Schrag ML, Starnes C, Tasker A, Teffera Y, Wang L, White RD, Whittington DA, Zanon R.

J Med Chem. 2008 Mar 27;51(6):1649-67. doi: 10.1021/jm701097z. Epub 2008 Mar 7.

PMID:
18324761
17.

Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.

Weiss MM, Harmange JC, Polverino AJ, Bauer D, Berry L, Berry V, Borg G, Bready J, Chen D, Choquette D, Coxon A, DeMelfi T, Doerr N, Estrada J, Flynn J, Graceffa RF, Harriman SP, Kaufman S, La DS, Long A, Neervannan S, Patel VF, Potashman M, Regal K, Roveto PM, Schrag ML, Starnes C, Tasker A, Teffera Y, Whittington DA, Zanon R.

J Med Chem. 2008 Mar 27;51(6):1668-80. doi: 10.1021/jm701098w. Epub 2008 Mar 7.

PMID:
18324759
18.

Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis.

La DS, Belzile J, Bready JV, Coxon A, DeMelfi T, Doerr N, Estrada J, Flynn JC, Flynn SR, Graceffa RF, Harriman SP, Larrow JF, Long AM, Martin MW, Morrison MJ, Patel VF, Roveto PM, Wang L, Weiss MM, Whittington DA, Teffera Y, Zhao Z, Polverino AJ, Harmange JC.

J Med Chem. 2008 Mar 27;51(6):1695-705. doi: 10.1021/jm701129j. Epub 2008 Feb 27.

PMID:
18311900
19.

Discovery of N-phenyl nicotinamides as potent inhibitors of Kdr.

Dominguez C, Smith L, Huang Q, Yuan C, Ouyang X, Cai L, Chen P, Kim J, Harvey T, Syed R, Kim TS, Tasker A, Wang L, Zhang M, Coxon A, Bready J, Starnes C, Chen D, Gan Y, Neervannan S, Kumar G, Polverino A, Kendall R.

Bioorg Med Chem Lett. 2007 Nov 1;17(21):6003-8. Epub 2007 Aug 22.

PMID:
17869515
20.

Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors.

Potashman MH, Bready J, Coxon A, DeMelfi TM Jr, DiPietro L, Doerr N, Elbaum D, Estrada J, Gallant P, Germain J, Gu Y, Harmange JC, Kaufman SA, Kendall R, Kim JL, Kumar GN, Long AM, Neervannan S, Patel VF, Polverino A, Rose P, Plas Sv, Whittington D, Zanon R, Zhao H.

J Med Chem. 2007 Sep 6;50(18):4351-73. Epub 2007 Aug 15. Erratum in: J Med Chem. 2008 Feb 14;51(3):699.

PMID:
17696416
21.

Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.

Rosen LS, Kurzrock R, Mulay M, Van Vugt A, Purdom M, Ng C, Silverman J, Koutsoukos A, Sun YN, Bass MB, Xu RY, Polverino A, Wiezorek JS, Chang DD, Benjamin R, Herbst RS.

J Clin Oncol. 2007 Jun 10;25(17):2369-76.

PMID:
17557949
22.

Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitors.

Hodous BL, Geuns-Meyer SD, Hughes PE, Albrecht BK, Bellon S, Caenepeel S, Cee VJ, Chaffee SC, Emery M, Fretland J, Gallant P, Gu Y, Johnson RE, Kim JL, Long AM, Morrison M, Olivieri PR, Patel VF, Polverino A, Rose P, Wang L, Zhao H.

Bioorg Med Chem Lett. 2007 May 15;17(10):2886-9. Epub 2007 Feb 25.

PMID:
17350837
23.

Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase.

Cee VJ, Albrecht BK, Geuns-Meyer S, Hughes P, Bellon S, Bready J, Caenepeel S, Chaffee SC, Coxon A, Emery M, Fretland J, Gallant P, Gu Y, Hodous BL, Hoffman D, Johnson RE, Kendall R, Kim JL, Long AM, McGowan D, Morrison M, Olivieri PR, Patel VF, Polverino A, Powers D, Rose P, Wang L, Zhao H.

J Med Chem. 2007 Feb 22;50(4):627-40. Epub 2007 Jan 25.

PMID:
17253679
24.

Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor.

Hodous BL, Geuns-Meyer SD, Hughes PE, Albrecht BK, Bellon S, Bready J, Caenepeel S, Cee VJ, Chaffee SC, Coxon A, Emery M, Fretland J, Gallant P, Gu Y, Hoffman D, Johnson RE, Kendall R, Kim JL, Long AM, Morrison M, Olivieri PR, Patel VF, Polverino A, Rose P, Tempest P, Wang L, Whittington DA, Zhao H.

J Med Chem. 2007 Feb 22;50(4):611-26. Epub 2007 Jan 25.

PMID:
17253678
25.

AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.

Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, Wang L, Bready J, Estrada J, Cattley R, Kaufman S, Chen D, Gan Y, Kumar G, Meyer J, Neervannan S, Alva G, Talvenheimo J, Montestruque S, Tasker A, Patel V, Radinsky R, Kendall R.

Cancer Res. 2006 Sep 1;66(17):8715-21.

26.

Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.

Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, Rattan A, Scully S, Fletcher F, Juan T, Kelley M, Burgess TL, Boyle WJ, Polverino AJ.

Am J Pathol. 2000 Aug;157(2):435-48.

27.

Ceramide second messengers and ceramide assays.

Watts JD, Aebersold R, Polverino AJ, Patterson SD, Gu M.

Trends Biochem Sci. 1999 Jun;24(6):228. No abstract available.

PMID:
10366850
28.
29.

Fas-induced apoptosis of T cells occurs independently of ceramide generation.

Watts JD, Gu M, Polverino AJ, Patterson SD, Aebersold R.

Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7292-6.

30.
31.

The highly conserved skb1 gene encodes a protein that interacts with Shk1, a fission yeast Ste20/PAK homolog.

Gilbreth M, Yang P, Wang D, Frost J, Polverino A, Cobb MH, Marcus S.

Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13802-7.

32.

Activation of mitogen-activated protein kinase cascades by p21-activated protein kinases in cell-free extracts of Xenopus oocytes.

Polverino A, Frost J, Yang P, Hutchison M, Neiman AM, Cobb MH, Marcus S.

J Biol Chem. 1995 Nov 3;270(44):26067-70.

33.
34.

Multiple Ras functions can contribute to mammalian cell transformation.

White MA, Nicolette C, Minden A, Polverino A, Van Aelst L, Karin M, Wigler MH.

Cell. 1995 Feb 24;80(4):533-41.

35.

Complexes between STE5 and components of the pheromone-responsive mitogen-activated protein kinase module.

Marcus S, Polverino A, Barr M, Wigler M.

Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7762-6.

36.

Complex formation between RAS and RAF and other protein kinases.

Van Aelst L, Barr M, Marcus S, Polverino A, Wigler M.

Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6213-7.

37.

RAS function and protein kinase cascades.

Marcus S, Wigler M, Xu HP, Ballester R, Kawamukai M, Polverino A.

Ciba Found Symp. 1993;176:53-61; discussion 61-6. Review.

PMID:
8299425
38.

Oncogenic ras triggers the activation of 42-kDa mitogen-activated protein kinase in extracts of quiescent Xenopus oocytes.

Shibuya EK, Polverino AJ, Chang E, Wigler M, Ruderman JV.

Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9831-5.

39.
40.
41.

On the source of the vasopressin-induced increases in diacylglycerol in hepatocytes.

Polverino AJ, Barritt GJ.

Biochim Biophys Acta. 1988 Jun 8;970(1):75-82.

PMID:
3130896
43.

Salicyl phenolic glucuronide pharmacokinetics in patients with rheumatoid arthritis.

Bochner F, Graham GG, Polverino A, Imhoff DM, Tregenza RA, Rolan PE, Cleland LG.

Eur J Clin Pharmacol. 1987;32(2):153-8.

PMID:
3582479
44.

Supplemental Content

Loading ...
Support Center